Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

HOMOLOGY MEDICINES, INC.

(FIXX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
5.17(c) 5.05(c) 4.77(c) 4.85(c) 4.51(c) Last
467 657 874 907 331 944 251 860 338 623 Volume
-0.96% -2.32% -5.54% +1.68% -7.01% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 33,9 M - -
Net income 2021 -96,0 M - -
Net cash position 2021 157 M - -
P/E ratio 2021 -2,64x
Yield 2021 -
Sales 2022 3,02 M - -
Net income 2022 -149 M - -
Net cash position 2022 4,90 M - -
P/E ratio 2022 -1,96x
Yield 2022 -
Capitalization 258 M 258 M -
EV / Sales 2021 2,98x
EV / Sales 2022 83,6x
Nbr of Employees 205
Free-Float 90,9%
More Financials
Company
Homology Medicines, Inc. is a clinical-stage genetic medicines company. The Company focuses on patients suffering from rare genetic diseases by curing the underlying cause of the disease. Its platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs), to deliver single administration genetic medicines in vivo either through gene therapy or nuclease-free gene... 
More about the company
Ratings of Homology Medicines, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about HOMOLOGY MEDICINES, INC.
12/02HOMOLOGY MEDICINES : Corporate Presentation - November 2021
PU
11/16Chardan Adjusts Homology Medicines' Price Target to $25 From $30; Buy Rating Kept
MT
11/15HOMOLOGY MEDICINES : Q3 Earnings Snapshot
AQ
11/15Homology Medicines Reports Third Quarter 2021 Financial Results and Recent Highlights
AQ
11/15HOMOLOGY MEDICINES, INC. Management's Discussion and Analysis of Financial Condition a..
AQ
11/15Homology Medicines, Inc. Reports Earnings Results for the Third Quarter and Nine Months..
CI
11/08Corporate Presentation - November 2021
PU
11/03Homology Medicines to Participate in Upcoming Investor Conferences
GL
11/03Homology Medicines to Participate in Upcoming Investor Conferences
GL
10/21HOMOLOGY MEDICINES : 10/21/2021 Homology Medicines Announces Presentations Across Gene The..
PU
10/21HOMOLOGY MEDICINES : Announces Presentations Across Gene Therapy and Gene Editing Programs..
AQ
10/21Homology Medicines Announces Presentations Across Gene Therapy and Gene Editing Program..
CI
10/20HOMOLOGY MEDICINES : 10/20/2021 Homology Medicines Announces Presentation of Data Supporti..
PU
10/20Homology Medicines Announces Presentation of Data Supporting Clinical Programs in MPS I..
GL
10/20HOMOLOGY MEDICINES : Announces Presentation of Data Supporting Clinical Programs in MPS II..
GL
More news
News in other languages on HOMOLOGY MEDICINES, INC.
10/18Homology Medicines lance un essai clinique sur un médicament contre le syndrome de Hunt..
10/13Homology Medicines va procéder à l'essai clinique de phase 1 du traitement de la phényl..
04/07MÄRKTE USA/Kaum verändert - Fed-Protokoll ohne Überraschungen
04/07MÄRKTE USA/Börsen treten vor Fed-Protokoll auf der Stelle
04/07MÄRKTE USA/Zurückhaltung vor Fed-Protokoll
More news
Analyst Recommendations on HOMOLOGY MEDICINES, INC.
More recommendations
Chart HOMOLOGY MEDICINES, INC.
Duration : Period :
Homology Medicines, Inc. Technical Analysis Chart | FIXX | US4380831077 | MarketScreener
Technical analysis trends HOMOLOGY MEDICINES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 4,51 $
Average target price 23,33 $
Spread / Average Target 417%
EPS Revisions
Managers and Directors
Arthur O. Tzianabos President, Chief Executive Officer & Director
W. Bradford Smith Chief Financial Officer, Secretary & Treasurer
Kush M. Parmar Chairman
Albert Seymour Chief Scientific Officer
Gabriel M. Cohn Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
HOMOLOGY MEDICINES, INC.-60.05%258
GILEAD SCIENCES, INC.19.40%87 255
BIONTECH SE310.30%83 098
REGENERON PHARMACEUTICALS31.23%66 409
WUXI APPTEC CO., LTD.26.31%65 758
VERTEX PHARMACEUTICALS-13.76%51 819